000168037812-312026Q3falsexbrli:sharesiso4217:USDiso4217:USDxbrli:sharessnes:statexbrli:puresnes:installmentsnes:segment00016803782026-01-012026-09-3000016803782026-11-1200016803782026-09-3000016803782025-12-3100016803782026-07-012026-09-3000016803782025-07-012025-09-3000016803782025-01-012025-09-3000016803782024-12-3100016803782025-09-300001680378snes:EvolveMember2026-01-012026-09-300001680378snes:EvolveMouseMember2026-01-012026-09-3000016803782026-06-3000016803782025-06-300001680378snes:ResearchAndDevelopmentEquipmentMember2026-09-300001680378snes:ResearchAndDevelopmentEquipmentMember2025-12-310001680378snes:OfficeAndComputerEquipmentMember2026-09-300001680378snes:OfficeAndComputerEquipmentMember2025-12-310001680378snes:AutosTrucksMember2026-09-300001680378snes:AutosTrucksMember2025-12-310001680378us-gaap:FurnitureAndFixturesMember2026-09-300001680378us-gaap:FurnitureAndFixturesMember2025-12-310001680378us-gaap:LeaseholdImprovementsMember2026-09-300001680378us-gaap:LeaseholdImprovementsMember2025-12-310001680378snes:DepreciablePropertyPlantAndEquipmentMember2026-09-300001680378snes:DepreciablePropertyPlantAndEquipmentMember2025-12-310001680378us-gaap:NotesPayableOtherPayablesMember2026-09-300001680378us-gaap:NotesPayableOtherPayablesMember2026-01-012026-09-300001680378snes:EquityIncentivePlan2018Member2026-06-090001680378snes:EquityIncentivePlan2018Member2026-09-300001680378snes:A2026InducementPlanMember2026-08-310001680378snes:A2026InducementPlanMember2026-09-300001680378us-gaap:EmployeeStockOptionMembersrt:MinimumMember2026-07-012026-09-300001680378us-gaap:EmployeeStockOptionMembersrt:MaximumMember2026-07-012026-09-300001680378us-gaap:EmployeeStockOptionMember2026-07-012026-09-300001680378snes:ContingentStockOptionsPlanMember2025-10-1500016803782025-10-1500016803782025-10-152025-10-1500016803782025-01-012025-12-310001680378snes:ShareBasedPaymentArrangementOptionInducementAwardMember2026-09-300001680378snes:EquityIncentivePlan2018Member2026-01-012026-09-300001680378us-gaap:EmployeeStockOptionMembersnes:EquityIncentivePlan2018Member2026-01-012026-09-300001680378us-gaap:ResearchAndDevelopmentExpense2026-07-012026-09-300001680378us-gaap:ResearchAndDevelopmentExpense2025-07-012025-09-300001680378us-gaap:ResearchAndDevelopmentExpense2026-01-012026-09-300001680378us-gaap:ResearchAndDevelopmentExpense2025-01-012025-09-300001680378us-gaap:SellingAndMarketingExpense2026-07-012026-09-300001680378us-gaap:SellingAndMarketingExpense2025-07-012025-09-300001680378us-gaap:SellingAndMarketingExpense2026-01-012026-09-300001680378us-gaap:SellingAndMarketingExpense2025-01-012025-09-300001680378us-gaap:GeneralAndAdministrativeExpense2026-07-012026-09-300001680378us-gaap:GeneralAndAdministrativeExpense2025-07-012025-09-300001680378us-gaap:GeneralAndAdministrativeExpense2026-01-012026-09-300001680378us-gaap:GeneralAndAdministrativeExpense2025-01-012025-09-300001680378us-gaap:CommonStockMember2025-12-310001680378us-gaap:AdditionalPaidInCapitalMember2025-12-310001680378us-gaap:RetainedEarningsMember2025-12-310001680378us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-3100016803782026-01-012026-03-310001680378us-gaap:CommonStockMember2026-01-012026-03-310001680378us-gaap:RetainedEarningsMember2026-01-012026-03-310001680378us-gaap:CommonStockMember2026-03-310001680378us-gaap:AdditionalPaidInCapitalMember2026-03-310001680378us-gaap:RetainedEarningsMember2026-03-3100016803782026-03-310001680378us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-3000016803782026-04-012026-06-300001680378us-gaap:RetainedEarningsMember2026-04-012026-06-300001680378us-gaap:CommonStockMember2026-06-300001680378us-gaap:AdditionalPaidInCapitalMember2026-06-300001680378us-gaap:RetainedEarningsMember2026-06-300001680378us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001680378us-gaap:CommonStockMember2026-07-012026-09-300001680378us-gaap:RetainedEarningsMember2026-07-012026-09-300001680378us-gaap:CommonStockMember2026-09-300001680378us-gaap:AdditionalPaidInCapitalMember2026-09-300001680378us-gaap:RetainedEarningsMember2026-09-300001680378us-gaap:CommonStockMember2024-12-310001680378us-gaap:AdditionalPaidInCapitalMember2024-12-310001680378us-gaap:RetainedEarningsMember2024-12-310001680378us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100016803782025-01-012025-03-310001680378us-gaap:CommonStockMember2025-01-012025-03-310001680378us-gaap:RetainedEarningsMember2025-01-012025-03-310001680378us-gaap:CommonStockMember2025-03-310001680378us-gaap:AdditionalPaidInCapitalMember2025-03-310001680378us-gaap:RetainedEarningsMember2025-03-3100016803782025-03-310001680378us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-3000016803782025-04-012025-06-300001680378us-gaap:CommonStockMember2025-04-012025-06-300001680378us-gaap:RetainedEarningsMember2025-04-012025-06-300001680378us-gaap:CommonStockMember2025-06-300001680378us-gaap:AdditionalPaidInCapitalMember2025-06-300001680378us-gaap:RetainedEarningsMember2025-06-300001680378us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001680378us-gaap:CommonStockMember2025-07-012025-09-300001680378us-gaap:RetainedEarningsMember2025-07-012025-09-300001680378us-gaap:CommonStockMember2025-09-300001680378us-gaap:AdditionalPaidInCapitalMember2025-09-300001680378us-gaap:RetainedEarningsMember2025-09-300001680378us-gaap:CommonStockMember2026-01-012026-09-300001680378snes:DealerManagerWarrants6Member2026-01-012026-09-300001680378snes:DealerManagerWarrants6Member2026-09-300001680378snes:DealerManagerWarrants6Member2025-12-310001680378snes:PrivatePlacementAgreementOneMember2026-01-012026-09-300001680378snes:PrivatePlacementAgreementOneMember2026-09-300001680378snes:PrivatePlacementAgreementOneMember2025-12-310001680378snes:DealerManagerWarrants7Member2026-01-012026-09-300001680378snes:DealerManagerWarrants7Member2026-09-300001680378snes:DealerManagerWarrants7Member2025-12-310001680378snes:DealerManagerWarrants8Member2026-01-012026-09-300001680378snes:DealerManagerWarrants8Member2026-09-300001680378snes:DealerManagerWarrants8Member2025-12-310001680378snes:DealerManagerWarrants9Member2026-01-012026-09-300001680378snes:DealerManagerWarrants9Member2026-09-300001680378snes:DealerManagerWarrants9Member2025-12-310001680378snes:SeriesCWarrantsMember2026-01-012026-09-300001680378snes:SeriesCWarrantsMember2026-09-300001680378snes:SeriesCWarrantsMember2025-12-310001680378snes:DealerManagerWarrants10Member2026-01-012026-09-300001680378snes:DealerManagerWarrants10Member2026-09-300001680378snes:DealerManagerWarrants10Member2025-12-310001680378snes:DealerManagerWarrants11Member2026-01-012026-09-300001680378snes:DealerManagerWarrants11Member2026-09-300001680378snes:DealerManagerWarrants11Member2025-12-310001680378snes:SeriesDWarrantsMember2026-01-012026-09-300001680378snes:SeriesDWarrantsMember2026-09-300001680378snes:SeriesDWarrantsMember2025-12-310001680378snes:DealerManagerWarrants12Member2026-01-012026-09-300001680378snes:DealerManagerWarrants12Member2026-09-300001680378snes:DealerManagerWarrants12Member2025-12-310001680378snes:SeriesF1WarrantsMember2026-01-012026-09-300001680378snes:SeriesF1WarrantsMember2026-09-300001680378snes:SeriesF1WarrantsMember2025-12-310001680378snes:SeriesF2WarrantsMember2026-01-012026-09-300001680378snes:SeriesF2WarrantsMember2026-09-300001680378snes:SeriesF2WarrantsMember2025-12-310001680378snes:DealerManagerWarrants13Member2026-01-012026-09-300001680378snes:DealerManagerWarrants13Member2026-09-300001680378snes:DealerManagerWarrants13Member2025-12-310001680378snes:DealerManagerWarrants15Member2026-01-012026-09-300001680378snes:DealerManagerWarrants15Member2026-09-300001680378snes:DealerManagerWarrants15Member2025-12-310001680378snes:DealerManagerWarrants17Member2026-01-012026-09-300001680378snes:DealerManagerWarrants17Member2026-09-300001680378snes:DealerManagerWarrants17Member2025-12-310001680378snes:DealerManagerWarrants18Member2026-01-012026-09-300001680378snes:DealerManagerWarrants18Member2026-09-300001680378snes:DealerManagerWarrants18Member2025-12-310001680378snes:DealerManagerWarrants19Member2026-01-012026-09-300001680378snes:DealerManagerWarrants19Member2026-09-300001680378snes:DealerManagerWarrants19Member2025-12-310001680378us-gaap:WarrantMember2026-01-012026-09-300001680378us-gaap:WarrantMember2025-01-012025-09-300001680378snes:CommonStockOptionsMember2026-01-012026-09-300001680378snes:CommonStockOptionsMember2025-01-012025-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:AmazonMemberus-gaap:SalesRevenueNetMember2026-07-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:AmazonMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:AmazonMemberus-gaap:SalesRevenueNetMember2026-01-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:AmazonMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorAMemberus-gaap:SalesRevenueNetMember2026-07-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorAMemberus-gaap:SalesRevenueNetMember2025-07-012025-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorAMemberus-gaap:SalesRevenueNetMember2026-01-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorAMemberus-gaap:SalesRevenueNetMember2025-01-012025-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:AmazonMemberus-gaap:AccountsReceivableMember2026-01-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:AmazonMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorBMemberus-gaap:AccountsReceivableMember2026-01-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorBMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorCMemberus-gaap:AccountsReceivableMember2026-01-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorCMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorDMemberus-gaap:AccountsReceivableMember2026-01-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorDMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorEMemberus-gaap:AccountsReceivableMember2026-01-012026-09-300001680378us-gaap:CustomerConcentrationRiskMembersnes:DistributorEMemberus-gaap:AccountsReceivableMember2025-01-012025-12-310001680378us-gaap:SubsequentEventMembersnes:ATMFacilityMember2026-10-012026-11-100001680378us-gaap:SubsequentEventMember2026-10-20
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File Number: 001-37941
SENESTECH, INC.
(Exact name of registrant as specified in its charter)
Delaware20-2079805
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
13430 North Dysart Road, Suite 105
Surprise, AZ
85379
(Address of principal executive offices)(Zip Code)
(928) 779-4143
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueSNESThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
The number of shares of common stock outstanding as of November 12, 2026: 6,823,881


Table of Contents
SENESTECH, INC.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026
TABLE OF CONTENTS
Item 1.


Table of Contents
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements
SENESTECH, INC.
CONDENSED BALANCE SHEETS
(In thousands, except shares and per share data)
September 30,
2026
December 31, 2025
ASSETS(unaudited)
Current assets:
Cash and cash equivalents$3,951 $7,575 
Short-term investments— 994 
Accounts receivable, net247 201 
Inventory966 994 
Prepaid expenses and other current assets398 297 
Total current assets5,562 10,061 
Right to use asset, operating lease2,211 2,336 
Property and equipment, net334 410 
Other noncurrent assets36 36 
Total assets$8,143 $12,843 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$357 $183 
Accrued expenses615 383 
Current portion of operating lease liability151 139 
Current portion of notes payable65 61 
Deferred revenue45 32 
Total current liabilities1,233 798 
Operating lease liability, less current portion2,217 2,332 
Notes payable, less current portion95 145 
Total liabilities3,545 3,275 
Commitments and contingencies (see notes)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding as of September 30, 2026 and December 31, 2025
— — 
Common stock, $0.001 par value, 100,000,000 shares authorized, 5,475,428 and 5,223,015 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
5 5 
Additional paid-in capital152,924 152,043 
Accumulated deficit(148,331)(142,480)
Total stockholders’ equity4,598 9,568 
Total liabilities and stockholders’ equity$8,143 $12,843 
See accompanying notes to condensed financial statements.
1

Table of Contents
SENESTECH, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except shares and per share data)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenues, net$1,097 $690 $2,360 $1,800 
Cost of sales301 257 659 645 
Gross profit796 433 1,701 1,155 
Operating expenses:
Research and development418 400 1,217 1,245 
Sales and marketing1,082 425 2,218 1,277 
General and administrative1,287 955 4,238 3,257 
Total operating expenses2,787 1,780 7,673 5,779 
Loss from operations(1,991)(1,347)(5,972)(4,624)
Interest income (expense):
Interest income40 55 135 62 
Interest expense(5)(6)(14)(17)
Interest income, net35 49 121 45 
Net loss and comprehensive loss$(1,956)$(1,298)$(5,851)$(4,579)
Weighted average shares outstanding - basic and diluted5,420,8994,668,0095,329,9232,619,841
Net loss per share - basic and diluted$(0.36)$(0.28)$(1.10)$(1.75)
See accompanying notes to condensed financial statements.
2

Table of Contents
SENESTECH, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
Nine Months Ended
September 30,
20262025
Cash flows from operating activities:
Net loss$(5,851)$(4,579)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation481 228 
Depreciation and amortization94 103 
Operating lease22 87 
Bad debt expense— 6 
Accretion of interest on held-to-maturity investments(6)(6)
Changes in operating assets and liabilities:
Accounts receivable(46)(125)
Prepaid expenses and other current assets(101)64 
Inventory28 27 
Other assets— 22 
Accounts payable174 22 
Accrued expenses232 55 
Deferred revenue13 10 
Net cash used in operating activities(4,960)(4,086)
Cash flows from investing activities:
Purchase of held-to-maturity investments— (2,964)
Maturity of held-to-maturity investment1,000 — 
Purchase of property and equipment(18)(125)
Net cash provided by (used in) investing activities982 (3,089)
Cash flows from financing activities:
Proceeds from the exercise of warrants, net— 10,482 
Proceeds from issuances of common stock, net400 2,706 
Repayments of notes payable(46)(42)
Net cash provided by financing activities354 13,146 
Increase (decrease) in cash and cash equivalents(3,624)5,971 
Cash and cash equivalents, beginning of period7,575 1,307 
Cash and cash equivalents, end of period$3,951 $7,278 
Supplemental cash flow information is as follows:
Interest paid$14 $17 
Income taxes paid$— $— 
Non-cash investing and financing activities:
Operating lease entered into for right-to-use asset$— $2,439 
See accompanying notes to condensed financial statements.
3

Table of Contents
SENESTECH, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1: BASIS OF PRESENTATION
Nature of Business
SenesTech, Inc. (subsequently referred to in this report as “we,” “us,” “our,” “our company,” or the “Company”) was incorporated in the state of Nevada in July 2004. In November 2015, we reincorporated in the state of Delaware. Our corporate headquarters and manufacturing site are in Surprise, Arizona. We have developed and are commercializing products for managing animal pest populations through fertility control. Our current products focus on rat and mouse populations, and are known as ContraPest®, Evolve® Rat and Evolve Mouse, under the brand family Rodent Birth ControlTM.
CONTRAPEST. ContraPest, our initial product, is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide. ContraPest targets the reproductive systems of both male and female rats, is a highly palatable formulation, does not cause illness or changed behavior in rats, and leads to significant reductions in fertility and rat populations. Accordingly, ContraPest is an additional tool to use as part of an integrated pest management program.
ContraPest is registered in all 50 states, the District of Columbia and the U.S. Virgin Islands (49 states and the District of Columbia have approved the restricted use pesticide designation).
EVOLVE. The Evolve product line, which began with Evolve Rat, launched in January 2024, and is currently our lead product. Evolve Rat is a soft bait product that is novel to the pest control industry and contains the active ingredient, cottonseed oil. Evolve Rat reduces fertility in both male and female rats. Additionally, its palatable formulation produces high acceptance for sustained consumption even when other sought-after food sources are present. Evolve Rat does not cause illness in rats and, therefore, it does not change behavior or result in bait aversion. By targeting the reproductive systems of both male and female rats, and with palatability promoting continued consumption, the use of Evolve Rat can lead to a sustained reduction of the rat population.
Evolve Rat meets the U.S. Environmental Protection Agency’s (“EPA’s”) minimum risk pesticide conditions under Section 25(b) of the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”). Due to its classification, Evolve Rat is exempt from federal registration because it poses little to no risk to human health and the environment. Evolve Rat is also formulated using acceptable food-based ingredients that are exempt from the requirement of a tolerance under the Federal Food, Drug, and Cosmetic Act (“FFDCA”), supporting its use in agricultural applications. There are 10 states that accept the federal exemption for pesticide registration and require no additional determination or approval. In states that do not accept the federal exemption, we must obtain registration from the various state agencies. We are authorized to sell Evolve Rat in 47 states and territories.
In May 2024, we launched Evolve Mouse, our latest iteration of the Evolve product line. Evolve Mouse is a modified version of our soft bait technology and contains the same active ingredient, cottonseed oil. Evolve Mouse limits reproduction capability of both male and female mice and is also considered a minimum risk pesticide under Section 25(b) of FIFRA. We are authorized to sell Evolve Mouse in 37 states and territories.
Liquidity and Capital Resources
Since our inception, we have incurred significant operating losses related to our research and development and commercialization efforts and we expect these losses to continue in the near term. We have not generated sufficient revenue to date from product sales to cover operating expenses and have primarily funded our operations through the sale of equity securities, including common stock and warrants to purchase common stock. As of September 30, 2026, we had an accumulated deficit of $148.3 million and cash and cash equivalents of $4.0 million.
Our ultimate, long-term success depends upon the outcome of a combination of factors, including the following: (i) successful commercialization of our fertility control products and maintaining and obtaining regulatory approval of our products and product candidates; (ii) market acceptance, commercial viability and profitability of our fertility control products and other products; (iii) our ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) our ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs.
4

Table of Contents
Based upon our current operating plan, we expect that our cash and cash equivalents as of November 12, 2026, in combination with anticipated revenue, will be sufficient to fund our current operations for approximately nine month. Because that period is less than one year from the date these financial statements are issued, management evaluated our ability to continue as a going concern in accordance with ASC 205-40, Presentation of Financial Statements—Going Concern. Management's plans include growing revenue, managing operating expenses, and raising additional capital, including through sales of equity securities under our ATM Facility (as defined below), and management believes these plans alleviate the substantial doubt that would otherwise exist regarding the Company’s ability to continue as a going concern. While we have evaluated and continue to evaluate our operating expenses and have focused our resources on the successful commercialization of fertility control products in the United States, additional financing will be needed in order to fund our operating losses before achieving our revenue and margin targets and becoming profitable and generating positive cash flows. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate our commercialization and development efforts, sell certain assets, or discontinue operations, or we may be required to take other measures that could impair our ability to be successful and operate as a going concern.
Condensed Financial Statements
Our accompanying unaudited condensed financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with the U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In our opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly our financial position as of September 30, 2026, and our operating results and cash flows for the nine month periods ended September 30, 2026 and 2025. The accompanying financial information as of December 31, 2025 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026.
Recent Accounting Pronouncements
In November 2024, the Financial Accounting Standards Board issued Accounting Standards Update No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”). The amendments require additional disclosures in the notes to the financial statements that disaggregate certain expense captions presented on the face of the income statement. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2026, and interim reporting periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.
The Company is currently evaluating the disclosure requirements of the new guidance and any related changes to its financial reporting processes. Because the amendments affect disclosure only, the Company does not expect adoption of ASU 2024-03 to have a material impact on its financial position, results of operations, or cash flows, although adoption is expected to result in additional disclosures in the notes to its financial statements.
There have been no other new accounting pronouncements that are not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our condensed financial statements.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in our financial statements include the valuation of inventory, common stock warrants and stock-based awards, such as stock options and restricted stock units. Actual results could differ from such estimates.
Advertising Costs
Advertising costs are expensed as incurred and were $264,000 and $55,000 for the three months ended September 30, 2026 and 2025, respectively, and $329,000 and $112,000 for the nine months ended September 30, 2026 and 2025, respectively.
5

Table of Contents
Comprehensive Loss
We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for the periods presented, and a separate statement of comprehensive loss is not included in the accompanying condensed financial statements.
NOTE 2: BALANCE SHEET COMPONENTS
Cash and Cash Equivalents
Highly liquid investments with maturities of three months or less as of the date of acquisition are classified as cash equivalents, of which we had $1.8 million and $7.1 million as of September 30, 2026 and December 31, 2025, respectively, included within cash and cash equivalents in the condensed balance sheets.
Short-term Investments
From time to time we have held investments in U.S. Treasuries, which are classified as held-to-maturity and measured at amortized cost, which approximates fair value. We have both the intent and the ability to hold these securities to maturity. U.S. Treasuries with original maturities greater than 90 days and less than one year are presented as short-term investments on the condensed balance sheet.
Accounts Receivable, Net
Accounts receivable, net consisted of the following (in thousands):
September 30,
2026
December 31,
2025
Accounts receivable$249 $219 
Allowance for uncollectible accounts(2)(18)
Accounts receivable, net$247 $201 
The following was the activity in the allowance for uncollectible accounts (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Balance as of beginning of period$2 $10 $18 $4 
Increase in provision— — 5 6 
Amounts written off, less recoveries— — (21)— 
Balance as of end of period$2 $10 $2 $10 
Inventory
Inventory consisted of the following (in thousands):
September 30,
2026
December 31,
2025
Raw materials$649 $726 
Work in progress2 — 
Finished goods315 268 
Total inventory$966 $994 
6

Table of Contents

Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):
September 30,
2026
December 31,
2025
Software licenses$78 $127 
Equity offering costs99 29 
Professional services94 14 
Insurance45 47 
Rent and other prepaid expenses82 80 
Total prepaid expenses and other current assets$398 $297 
Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
September 30,
2026
December 31,
2025
Research and development equipment$1,291 $1,291 
Office and computer equipment84 84 
Autos54 54 
Furniture and fixtures47 47 
Leasehold improvements123 105 
Total in service1,599 1,581 
Accumulated depreciation and amortization(1,265)(1,171)
Property and equipment, net$334 $410 
Accrued Expenses
Accrued expenses consisted of the following (in thousands):
September 30,
2026
December 31,
2025
Compensation and related benefits$572 $327 
Legal and consulting professional services33 52 
Product warranty and other10 4 
Total accrued expenses$615 $383 
Notes Payable
We have financing arrangements related to the purchase of certain equipment. The notes payable for that certain equipment have a weighted average annual interest rate of 10.4% with original terms of five years and are secured by the underlying equipment.
7

Table of Contents
As of September 30, 2026, future principal payments were as follows (in thousands):
2026$16 
202768 
202864 
202912 
Total principal payments160 
Less: current portion of notes payable(65)
Notes payable, less current portion$95 
NOTE 3: FAIR VALUE MEASUREMENTS
The carrying amounts of our financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. The fair value of investments approximates cost due to their short-term nature and fixed interest rates. Notes payable and operating lease liability are measured at amortized cost, which approximates fair value based on current market rates and terms.
NOTE 4: LEASES
We have an operating lease arrangement for our corporate offices and manufacturing and research operations that extends through 2035.
The components of lease cost were as follows (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Operating lease cost$90 $90 $270 $160 
Short-term lease cost (1)
— — 1 116 
Variable lease cost (2)
13 11 40 22 
Total lease cost$103 $101 $311 $298 
(1) Includes amounts related to leases with original terms of 12 months or less, for which we have elected the short-term lease exemption.
(2) Includes amounts related to common area maintenance, property taxes and any other lease-related charges that vary based on usage or actual costs and are not included in the operating lease liability.
As of September 30, 2026, the maturities under the operating lease liability were as follows (in thousands):
2026$83 
2027338 
2028348 
2029359 
2030369 
Thereafter1,875 
Total operating lease payments3,372 
Less: imputed interest(1,004)
Total operating lease liability$2,368 
NOTE 5: STOCK-BASED COMPENSATION
In 2018, our stockholders approved the SenesTech, Inc. 2018 Equity Incentive Plan (the “2018 Plan”), which provides for the grant of stock-based awards, including stock options and restricted stock units, to employees, directors and consultants. The 2018 Plan has been amended and restated from time to time, most recently on June 9, 2026, when our stockholders
8

Table of Contents
approved an increase in the aggregate number of shares of common stock authorized for issuance under the 2018 Plan to 1,407,071 shares. As of September 30, 2026, 245,516 shares of common stock remained available for future issuance under the 2018 Plan.
In August 2026, our Board of Directors (the “Board”) adopted the SenesTech, Inc. 2026 Inducement Plan (the “2026 Inducement Plan”), which has terms substantially similar to those of the 2018 Plan and authorizes the issuance of up to 110,000 shares of common stock. As of September 30, 2026, 1,530 shares of common stock remained available for future issuance under the 2026 Inducement Plan. The 2018 Plan and 2026 Inducement Plan are collectively referred to as the “Plans.”
As of September 30, 2026, outstanding awards consist primarily of stock options. Stock options are generally granted with an exercise price equal to the fair market value of our common stock as of the date of grant. Options generally vest ratably over periods ranging from 12 to 36 months, coinciding with the requisite service periods, and generally have contractual terms of ten years. Certain stock option awards provide for accelerated vesting upon a change in control.
Contingent Stock Options
On October 15, 2025, the Board approved the grant of stock options to purchase up to 420,000 shares of common stock to the Board members pursuant to a proposed amendment to the 2018 Plan (the “Contingent Stock Options”). The Board approved an amendment to the 2018 Plan, which was submitted to the stockholders of the Company for approval at the 2026 annual meeting of stockholders, to increase the number of shares available for issuance thereunder to ensure that the Company has sufficient shares to attract, retain, and motivate key employees and directors. In May 2026, prior to the 2026 annual meeting of stockholders, the Contingent Stock Options were voluntarily forfeited by each recipient.
The terms of the cancelled Contingent Stock Options included an exercise price of $4.05 per share, vesting in four equal installments of 25% on each of January 15, 2026, April 15, 2026, July 15, 2026, and October 15, 2026, and a contractual term expiring October 15, 2035. The grants were contingent upon stockholder approval of the amended 2018 Plan by October 15, 2026. If such approval was not obtained by that date, the Contingent Stock Options would be rescinded, terminated, and deemed void ab initio, as if the grant had never occurred.
Because a grant date, as defined in ASC 718, Compensation—Stock Compensation, would not have occurred unless and until the stockholders approved the amendment to the 2018 Plan, and because each recipient voluntarily forfeited the Contingent Stock Options, which were immediately cancelled by the Company prior to the stockholder vote, no grant date was established and, accordingly, no stock-based compensation expense was recognized with respect to these awards.
Stock Options
The following table presents the outstanding stock option activity:
Number of OptionsWeighted
Average
Exercise
Price Per
Share
Weighted
Average
Remaining
Contractual
Term
(years)
Outstanding as of December 31, 2025175,578 20.75 8.8
Granted1,161,758 1.57 9.7
Exercised— — — 
Forfeited(66,993)5.70 — 
Expired(140)3,985.71 — 
Outstanding as of September 30, 20261,270,203 
(1)
3.56 9.5
Exercisable as of September 30, 2026310,691 9.68 9.1
(1) Includes options related to 8 shares that are inducement awards and not granted under the Plans.
9

Table of Contents
The weighted-average fair value of options granted during the nine months ended September 30, 2026 was $1.35 per share as of the grant date. The fair value of options granted during the period was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:
Expected volatility116 %
Expected dividend yield— %
Expected term (in years)6.0 years
Risk-free interest rate4.2 %
The expected volatility assumption is based on the calculated volatility of our common stock at the date of grant based on historical prices over the most recent period commensurate with the term of the award. The expected dividend yield assumption is based on our history and expected dividend payouts: we have not paid, and do not expect to pay, dividends. The expected term assumption is calculated based on the mid-point between the vesting date and the end of the contractual term according to the simplified method as described in SEC Staff Accounting Bulletin 110 because we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate assumption is determined using the U.S. Treasury yields for bonds with a maturity commensurate with the term of the award.
The stock-based compensation expense was recorded as follows (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Research and development$10 $2 $17 $8 
Sales and marketing9 2 11 7 
General and administrative257 43 453 213 
Total stock-based compensation expense$276 $47 $481 $228 
The allocation between research and development, sales and marketing, and general and administrative expense was based on the department and services performed by the employee or non-employee.
As of September 30, 2026, total unrecognized compensation cost related to unvested options was $1.2 million, which is expected to be recognized over a weighted average period of 1.6 years, assuming the requisite service period is met.
10

Table of Contents
NOTE 6: STOCKHOLDERS’ EQUITY
Activity in equity during the nine months ended September 30, 2026 and 2025 was as follows (dollars in thousands):
Common StockAdditional
Paid-In
Capital
Accumulated
Deficit
Total
SharesAmount
2026
Balances as of December 31, 20255,223,015 $5 $152,043 $(142,480)$9,568 
Stock-based compensation— — 23 — 23 
Issuance of common stock, net of transaction costs80,411 — 173 — 173 
Net loss— — — (2,063)(2,063)
Balances as of March 31, 20265,303,426 5 152,239 (144,543)7,701 
Stock-based compensation—— 182 — 182 
Net loss—— — (1,832)(1,832)
Balances as of June 30, 20265,303,426 5 152,421 (146,375)6,051 
Stock-based compensation—— 276 — 276 
Issuance of common stock, net of transaction costs172,002— 227 — 227 
Net loss—— — (1,956)(1,956)
Balances as of September 30, 20265,475,428$5 $152,924 $(148,331)$4,598 
2025
Balances as of December 31, 20241,035,893 $1 $138,607 $(136,097)$2,511 
Stock-based compensation— — 91 — 91 
Issuance of common stock, net of transaction costs365,319— 1,066 — 1,066 
Issuance of common stock upon exercise of warrants, net of transaction costs374,718 1 888 — 889 
Net loss— — — (1,665)(1,665)
Balances as of March 31, 20251,775,930 2 140,652 (137,762)2,892 
Stock-based compensation—— 90 — 90 
Issuance of common stock, net of transaction costs489,3411 1,639 — 1,640 
Issuance of common stock upon exercise of warrants, net of transaction costs1,498,8721 3,970 — 3,971 
Net loss—— — (1,616)(1,616)
Balances as of June 30, 20253,764,1434 146,351 (139,378)6,977 
Stock-based compensation—— 47 — 47 
Issuance of common stock upon exercise of warrants, net of transaction costs1,458,8721 5,621 — 5,622 
Net loss—— — (1,298)(1,298)
Balances as of September 30, 20255,223,015$5 $152,019 $(140,676)$11,348 
In June 2024, we entered into an at-the-market offering arrangement with a sales agent, pursuant to which we may offer and sell, from time to time at our sole discretion, in transactions that are deemed to be “at-the-market” offerings under the Securities Act of 1933, as amended (the “Securities Act”), shares of our common stock (“ATM Facility”). During the nine months ended September 30, 2026, we sold 252,413 shares of common stock under this ATM Facility for gross proceeds of $451,000, before deducting offering expenses of $51,000. As of September 30, 2026, there is capacity under the ATM Facility of approximately $7.1 million.
11

Table of Contents
NOTE 7: COMMON STOCK WARRANTS
The following table presents the common stock warrant activity:
Issue DateWarrant TypeTerm
Date
Exercise
Price
Balance December 31, 2025IssuedExercisedExpiredBalance September 30, 2026
October 2020Dealer ManagerApril 2026$5,174.40 34——(34)—
February 2021Private Placement AgreementAugust 20265,318.40 540——(540)—
February 2021Dealer ManagerAugust 20266,835.40 136——(136)—
March 2021Dealer ManagerMarch 20266,000.00 60——(60)—
November 2022Dealer ManagerNovember 2027525.00 892———892
April 2023Series COctober 2028194.40 7,142———7,142
April 2023Dealer ManagerApril 2028262.50 534———534
August 2023Dealer ManagerAugust 2028108.04 1,222———1,222
November 2023Series DNovember 202813.00 151,026———151,026
November 2023Dealer ManagerNovember 202816.25 28,844———28,844
August 2024Series F-1August 20294.35 319,434———319,434
August 2024Series F-2February 20264.35 316,852——(316,852)—
August 2024Dealer ManagerAugust 20295.75 25,275———25,275
March 2025Dealer ManagerSeptember 20263.625 18,736——(18,736)—
July 2025Dealer ManagerOctober 20263.781 72,944———72,944
August 2025Series INovember 20265.25 2,188,308———2,188,308
August 2025Dealer ManagerNovember 20265.4219 72,944———72,944
3,204,923——(336,358)2,868,565
SharesWeighted
Average
Exercise
Price Per
Share
Weighted
Average
Remaining
Contractual
Term
(years)
Outstanding as of December 31, 20253,204,923 $7.50 1.2
Issued— — — 
Exercised— — — 
Expired(336,358)17.20 — 
Outstanding as of September 30, 20262,868,565 6.36 0.6

12

Table of Contents
NOTE 8: LOSS PER SHARE
Basic loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including any prefunded warrants and shares held in abeyance from the date of issuance. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding used in the basic loss per share calculation, adjusted for the effect of potentially dilutive securities outstanding during the period, as determined using the treasury stock method, if dilutive.
For all periods presented, the Company incurred net losses. As a result, all potentially dilutive securities, including stock options and warrants, were excluded from the computation of diluted loss per share because their inclusion would have been anti-dilutive. Accordingly, basic and diluted loss per share were the same for each period presented.
The following potentially dilutive securities outstanding were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive:
September 30,
20262025
Common stock warrants2,868,565 3,204,923 
Stock options1,270,203 175,603 
4,138,768 3,380,526 
NOTE 9: SEGMENT INFORMATION
We operate in a single operating segment: the formulation, development, marketing and sale of fertility control products for use in managing pest populations. This single operating segment has been identified based on our internal management structure and reporting to our chief operating decision maker (“CODM”), our Chief Executive Officer.
Our CODM evaluates segment performance based on the revenues, gross profit and operating loss of the segment and uses internal financial statements to make decisions regarding resource allocation. Revenues, gross profit and operating loss used by the CODM are presented on our accompanying statement of operations. The measure of segment assets is represented as total assets presented on our accompanying balance sheets. There are no intersegment revenues, as all transactions are conducted within one operating segment.
We have not identified any reportable segments other than the single operating segment discussed.
The percentage of revenue attributable to our customers that represented 10% or more of revenue in at least one of the periods presented, was as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Amazon56 %— %43 %— %
Customer A1 28 1 29 
Amazon’s concentration reflects the Company’s sales through Amazon’s marketplace, where Amazon serves as the settlement counterparty for a large volume of individual consumer transactions. Accordingly, this concentration does not reflect dependence on a single end customer but rather the aggregation of numerous consumer purchases.
13

Table of Contents
The following accounts represented at least 10% of total accounts receivable in at least one of the periods presented:
September 30,
2026
December 31, 2025
Amazon26 %— %
Customer B15 9 
Customer C11 — 
Customer D6 14 
Customer E4 15 
While Amazon represented approximately 26% of accounts receivable as of September 30, 2026, the Company believes the related credit risk is limited. Amounts due from Amazon arise from a high volume of direct-to-consumer transactions that are settled under Amazon’s standard payment terms, with collections occurring on a frequent and predictable basis. As a result, the quarter-end receivable balance primarily reflects the timing of routine settlement activity rather than extended customer credit exposure. Accordingly, management does not believe the increased concentration results in a material increase in collection risk.
Although increased sales through Amazon increase the concentration of accounts receivable at period end, management believes the related collection risk is limited due to Amazon’s established settlement process. The Company continues to diversify its revenue through its own direct-to-consumer website, distributor relationships, and other sales channels and therefore does not believe the quarter-end receivable concentration is indicative of undue customer credit risk.
NOTE 10: RELATED PARTIES
Related party transactions are conducted in the normal course of business and, unless otherwise noted, are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. During the three and nine month periods ended September 30, 2026, consulting fees of $12,000 and $54,000, respectively, were incurred in connection with services provided by Hustle and Flower LLC, of which a member of our Board serves as chief executive officer. Such services were reviewed and approved by the Audit Committee pursuant to its charter and the Company’s related party transaction policy. These consulting fees totaled $19,000 for each of the three- and nine- month periods ended September 30, 2025.
NOTE 11: CONTINGENCIES
In December 2024, Liphatech Inc. (“Liphatech”) commenced an action against us in the United States District Court for the Eastern District of Wisconsin. The complaint alleged, among other things, breach of contract, misappropriation of trade secrets, unfair competition and unjust enrichment. These claims were based on allegations that we misappropriated and utilized proprietary information and trade secrets of Liphatech. The complaint also alleged that we breached a non-disclosure agreement that we had entered into with Liphatech. The complaint sought unspecified damages as well as injunctive relief. In March 2026, the parties resolved all disputes between them and the matter was settled. The litigation has been dismissed with prejudice.
In addition to the matter described above, we may be subject to other legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business. Management is not aware of any other pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on our financial position, results of operations or liquidity.
NOTE 12: SUBSEQUENT EVENTS
Since September 30, 2026, we have issued 1,348,457 shares of common stock pursuant to the ATM Facility for gross proceeds of $1.2 million.
On October 20, 2026, the Company received a letter from the listing qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of its common stock had been below $1.00 per share for 30 consecutive business days. As a result, the Company does not currently meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of SenesTech’s common stock, which will continue to trade on the Nasdaq Capital Market under the
14

Table of Contents
symbol “SNES.” Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 19, 2027, to regain compliance.
We have evaluated subsequent events from the balance sheet date through November 13, 2026, the date at which the condensed financial statements were issued, and determined that there were no other items that require adjustment to or disclosure in the condensed financial statements.
15

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our condensed financial statements and related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026.
Forward-Looking Statements
The statements contained in this Quarterly Report on Form 10-Q that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact contained in or incorporated herein by reference in this Quarterly Report on Form 10-Q, including statements regarding our future operating results, future financial position, cash runway, business strategy, objectives, goals, plans, prospects, markets, and plans and objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “seeks,” “suggests,” “targets,” “contemplates,” “projects,” “predicts,” “may,” “might,” “plans,” “will,” “would,” “should,” “could,” “can,” “potential,” “continue,” “objective,” “outlook” or the negative of those terms, or similar expressions intended to identify forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements regarding:
•our commercialization strategy strengthening our e-commerce business to build the Evolve brand, educate the market and establish credibility for a new category of pest management products; expanding our direct B2B operations through a professional sales organization focused on targeted vertical markets for both Evolve and ContraPest; and increasing our market opportunity through strategic partnerships, new products and value-added services;
•the development of our assessment and implementation services that leverage proprietary AI technology, field data, and professional expertise to help B2B customers evaluate pest populations, optimize product deployment, and measure treatment effectiveness, and our belief that these value-added services create incremental revenue opportunities, strengthen customer relationships, and further differentiate us in the marketplace by expanding our role beyond product sales to become a strategic pest management partner;
•our belief that Evolve® is novel in the pest control industry;
•our belief that Evolve Rat meets the United States Environmental Protection Agency’s (the “EPA’s”) minimum risk pesticide conditions under 25(b) of the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”) and is exempt from federal registration because it poses little to no risk to human health and the environment, and is formulated using acceptable food-based ingredients that are exempt from the requirement of tolerance under the FFDCA, supporting its use in agricultural applications;
•our ability to further develop our manufacturing processes to contain costs while being able to scale to meet future demand of fertility control products;
•our plan to continue to utilize stock-based awards to attract, retain and motivate key employees and directors;
•our expectation that our expenses may continue to increase in connection with our ongoing activities, particularly as we focus on marketing and sales of fertility control products, that we will continue to incur costs associated with operating as a public company, that consulting costs will moderate in the coming quarter, and that non-recurring costs associated with leadership transition and succession are not expected to recur;
•our ability to achieve market acceptance, commercial viability and profitability of our fertility control products and any other products;
•our ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue;
•the success of our research and development;
•our ability to retain and attract key personnel to develop, operate and grow our business;
16

Table of Contents
•our ability to maintain and protect our intellectual property portfolio;
•our ability to strengthen our e-commerce business, including through direct management of our Amazon and Shopify operations, and to drive recurring revenue through subscriptions and repeat purchases;
•our ability to expand our B2B business with a disciplined, vertical-market sales strategy targeting opportunities across commercial, government, pest management, agribusiness, retail, e-commerce, zoo and sanctuary, and international markets;
•our ability to raise additional capital, including through equity offerings under our existing ATM Facility, strategic partnerships, and other capital-raising transactions, and the extent to which any such financing could dilute your ownership interest;
•our ability to continue as a going concern;
•the effects of leadership transition and succession and of personnel transitions within the sales and marketing organizations;
•our belief that our cash and cash equivalents as of September 30, 2026, together with anticipated revenue and current operating expense levels, will be sufficient to fund our operations through the end of the third quarter of fiscal 2027, and our estimates or expectations related to our revenue, cash flow, expenses, capital requirements and need for additional financing; and
•our future financial performance, including our ability to fund our operations.
These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and situations that are difficult to predict and that may cause our actual results, or those of our industry, actual results to be materially different from the future results that are expressed or implied by these statements. Accordingly, actual results may differ materially from those anticipated or expressed in such statements as a result of a variety of factors, including those discussed in Part I, Item 1A—“Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026, as updated by Part II, Item 1A of this Quarterly Report on Form 10-Q, and those contained from time to time in our other filings with the SEC. Such factors include, among others, the following:
•the successful commercialization of our products;
•market acceptance of our products;
•our financial performance, including our ability to fund operations and continue as a going concern;
•our ability to raise additional capital on acceptable terms, or at all;
•the impact of personnel turnover within our sales and marketing organizations on our B2B sales;
•our ability to establish credibility for a new category of pest management products and to achieve broader commercial adoption of our products;
•the concentration of ownership of our common stock among a small number of stockholders, who are able to exert significant influence over matters requiring stockholder approval and may seek to influence our business strategies and operations
•maintaining and obtaining regulatory approval of our products and product candidates, including registration from the various state agencies in states that do not accept the federal exemption; and
•other factors and risks identified from time to time in our filings with the SEC, including this Quarterly Report on Form 10-Q.
17

Table of Contents
All forward-looking statements included herein are based on information available to us as of the date hereof and speak only as of such date. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. The forward-looking statements contained in or incorporated by reference into this Quarterly Report on Form 10-Q reflect our views as of the date of this Quarterly Report on Form 10-Q about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause our actual results, performance or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future events, results, performance or achievements.
We are subject to the information requirements of the Exchange Act, and we file or furnish reports, proxy statements and other information with the SEC. Such reports and other information are available free of charge on our website at www.senestech.com as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Information contained on, or accessible through, our website is not incorporated by reference into this Quarterly Report on Form 10-Q.
Overview
Over the past year, SenesTech has transformed from a research-focused organization into a revenue-driven company with a strategy focused on the commercialization of its proprietary pest management technologies for managing animal pest populations through fertility control. Our current product offerings are focused on rat and mouse population management and consist of Evolve Rat, Evolve Mouse (collectively, “Evolve”), and ContraPest.
Our strategy is centered on three priorities: (i) strengthening our e-commerce business to build the Evolve brand, educate the market, and establish credibility for a new category of pest management products; (ii) expanding our direct business-to-business (“B2B”) operations through a professional sales organization focused on targeted vertical markets for both Evolve and ContraPest; and (iii) increasing our market opportunity through strategic partnerships, new products, and value-added services.
We continue to make meaningful progress in executing our commercialization strategy. Following the transition of our Amazon and Shopify operations to direct management, we are seeing continued growth through these sales channels. Gross margins remain favorable, supported by an increasing contribution from Evolve product sales to overall revenue growth. We have also continued to strengthen our commercial infrastructure across multiple sales channels. Collectively, these developments reflect continued execution of our commercialization strategy and position the Company to pursue future growth opportunities.
We initially prioritized our e-commerce business by bringing our Amazon and Shopify operations under direct management, providing greater control over pricing, merchandising, customer relationships, and the overall customer experience. We believe these capabilities not only improve margins but also generate valuable customer insights, strengthen brand loyalty, and enhance our ability to drive recurring revenue through subscriptions and repeat purchases. As consumer awareness and adoption continue to grow, we believe our expanding base of customer reviews, subscriptions, and brand recognition will also support broader commercial adoption of our products.
Building on this foundation, we are expanding our B2B business with a disciplined, vertical-market sales strategy that targets opportunities across commercial, government, pest management, agribusiness, retail, zoo and sanctuary, and international markets. Our ongoing commercialization investments are designed to accelerate customer acquisition, deepen customer relationships, and support revenue growth across multiple end markets. This investments include expanding our professional sales organization and developing industry-specific materials, value propositions and return-on-investment models.
These initiatives increased our operating expenses in the first nine months of 2026 and reflect our long-term commitment to building the foundation for future growth. We expect these investments, which are distinct from the one-time transition and leadership-related costs incurred during the year, to moderate during the fourth quarter.
We are also placing greater emphasis on our e-commerce channel, particularly Amazon. E-commerce allows us to sell at higher prices than our other channels, but those sales carry higher marketplace fees and related fulfillment and advertising costs. Unlike the commercialization investments described above, we do not expect these costs to moderate. Because they
18

Table of Contents
are largely variable, we expect them to increase as e-commerce revenue grows. We believe this emphasis is warranted because our e-commerce presence also builds product awareness that benefits our other channels.
In addition to product sales, we are developing assessment and implementation services that leverage proprietary AI technology, field data, and professional expertise to help B2B customers evaluate pest populations, optimize product deployment, and measure treatment effectiveness. We believe these value-added services create incremental revenue opportunities, strengthen customer relationships, and further differentiate SenesTech in the marketplace by expanding our role beyond product sales to become a strategic pest management partner.
Management evaluates the progress of our commercialization strategy using several operating and financial indicators that we believe reflect the development of a scalable commercial business. These include growth in Evolve revenue, the mix of revenue generated through our direct-to-consumer channel, gross margin performance, repeat purchases and subscription activity, expansion of customer relationships across targeted commercial and government verticals, and adoption of our products and services by new customers. While these indicators may fluctuate from period to period, management believes that sustained improvement across these measures will lead to increasing market acceptance of our products and demonstrate continued execution of our commercialization strategy.
We believe our integrated strategy of building consumer awareness, expanding commercial sales, and offering differentiated products and services positions the Company for sustainable long-term growth. The operational progress achieved during the quarter, combined with our continued commercialization investments, reinforces our confidence that we are executing our strategy as planned while creating opportunities for future revenue growth and margin expansion.
19

Table of Contents
Results of Operations
Comparison of the Three Months Ended September 30, 2026 and 2025
The following table summarizes our results of operations for the periods presented (dollars in thousands):
Three Months Ended September 30,Change
20262025AmountPercent
Revenues, net$1,097 $690 $407 59 %
Cost of sales301 257 44 17 
Gross profit796 433 363 84 
Operating expenses:
Research and development418 400 18 5 
Sales and marketing1,082 425 657 155 
General and administrative1,287 955 332 35 
Total operating expenses2,787 1,780 1,007 57 
Loss from operations(1,991)(1,347)(644)48 
Interest income, net35 49 (14)(29)
Net loss$(1,956)$(1,298)$(658)51 
Revenues
Revenues for the periods presented consisted of the following (dollars in thousands):
Three Months Ended September 30,Change
20262025AmountPercent
By product line:
Evolve$979 89 %$586 85 %$393 67 %
ContraPest118 11 104 15 14 13 
$1,097 100 %$690 100 %$407 59 
By sales channel:
E-commerce$778 71 %$178 26 %$600 337 
B2B319 29 512 74 (193)(38)
$1,097 100 %$690 100 %$407 59 
Sales, net of sales discounts and promotions, were $1.1 million for the third quarter of 2026, compared to $690,000 for the third quarter of 2025. The $407,000 increase was primarily driven by higher sales of our Evolve product offerings, reflecting continued growth in our e-commerce sales channels. Evolve represented approximately 89% of third quarter 2026 revenues, compared to 85% in the third quarter of 2025. With the sales and marketing organizations now established and continuing to mature and grow, the B2B sales have increased approximately 23% to $319,000 compared to $259,000 for the second quarter of 2026. B2B sales decreased $193,000, or 38%, compared to the third quarter of 2025, reflecting the impact of transitioning Amazon management in-house in February of 2026, which shifted sales from the B2B channel to the e-commerce channel.
Cost of Sales
Cost of sales consists of costs related to products sold, including scrap and any reserves for obsolescence, as well as shipping costs when charged to the customer. Cost of sales was $301,000, or 27.4% of net sales, for the third quarter of 2026, compared to $257,000, or 37.2%, for the third quarter of 2025.
20

Table of Contents
Gross Profit
Gross profit for the third quarter of 2026 was $796,000, representing a margin of 72.6%, compared to $433,000, or 62.8% margin, in the third quarter of 2025. Gross profit improved primarily as a result of the continued ramp-up of sales through Amazon following the transition to selling directly on Amazon, which began in February 2026. Selling directly allows the Company to realize a higher selling price per unit than under the prior third-party distributor arrangement, and the resulting increase in gross profit is offset by the marketplace fees, commissions and other operating costs now recorded in sales and marketing expenses.
Research and Development Expenses
Research and development expenses consisted of the following (in thousands):
Three Months Ended September 30,Change
20262025AmountPercent
Personnel related (including stock-based compensation)$244 $202 $42 21 %
Facility related96 102 (6)(6)
Depreciation31 24 7 29 
Supplies, maintenance and other47 72 (25)(35)
Total$418 $400 $18 5 
Research and development expenses were $418,000 for the third quarter of 2026, compared to $400,000 for the third quarter of 2025, representing an increase of $18,000. The increase was primarily attributable to higher personnel-related costs, reflecting increased bonus expense associated with the progress towards the achievement of 2026 performance objectives. The increase was partially offset by lower supplies and maintenance expenses.
Sales and Marketing Expenses
Sales and marketing expenses consisted of the following (in thousands):
Three Months Ended September 30,Change
20262025AmountPercent
Personnel related (including stock-based compensation)$270 $184 $86 47 %
Retailer and third party fees and commissions282 — 282 *
Marketing and advertising278 76 202 266 
Professional fees143 74 69 93 
Other109 91 18 20 
Total$1,082 $425 $657 155 
* - Not applicable.
Sales and marketing expenses were $1.1 million for the third quarter of 2026, compared to $425,000 for the third quarter of 2025, representing an increase of $657,000. The increase in personnel related expenses increased due to an increase in sales headcount and increased commissions and incentives. The increase in retailer and third party fees and commissions is due to the bringing the Company’s Amazon business in-house. The increases in marketing and advertising and professional fees reflect the increased investment in brand and product awareness, and are expected to moderate as the Company reduces its reliance on consultants who supported personnel transitions within the sales and marketing organizations and completes its strategic initiatives.
Retailer and third-party fees and commissions of $282,000 for the third quarter of 2026 are the incremental operating costs associated with bringing third-party marketplace management, including Amazon, in-house. These costs, which were not incurred in the prior-year period, primarily reflect the economics of selling directly on Amazon rather than through a third-
21

Table of Contents
party distributor. Selling directly enables the Company to realize a higher selling price and a higher gross profit per unit, which is offset by the marketplace fees, commissions and other operating costs the Company now bears directly. The transition to direct management of our Amazon business, which began in February 2026 and was completed during the second quarter, provides greater control over pricing, merchandising, customer relationships and the overall customer experience while positioning the Company to sustain healthy margins, strengthen customer engagement, and capture valuable customer insights that support future revenue growth.
Marketing and advertising expenses increased by $202,000, primarily reflecting the hiring of the marketing team, which has established the personnel infrastructure needed to support the Company’s commercialization strategy, as well as increased spending on advertising initiatives to support the continued ramp-up of Amazon sales activity and drive growth through this channel.
Personnel costs increased by $86,000, reflecting changes in the composition of the sales team and higher compensation costs associated with the evolving sales organization, including increased bonus expense, sales commissions and stock-based compensation.
Professional fees increased by $69,000 to support the sales and marketing organizations during personnel transitions and to advance strategic sales and marketing initiatives, including product packaging redesign, marketing strategy development, and the transition to direct sales on Amazon. As the personnel transitions within the sales and marketing organizations and these strategic initiatives have largely been completed, we expect consulting costs to moderate in the coming quarters.
General and Administrative Expenses
General and administrative expenses consisted of the following (in thousands):
Three Months Ended September 30,Change
20262025AmountPercent
Personnel related$493 $265 $228 86 %
Professional fees384 465 (81)(17)
Stock-based compensation257 43 214 498 
Insurance51 49 2 4 
Other102 133 (31)(23)
Total$1,287 $955 $332 35 
General and administrative expenses were $1.3 million for the third quarter of 2026, compared to $1.0 million for the third quarter of 2025, representing an increase of $332,000. The overall increase was primarily attributable to higher personnel-related costs and stock-based compensation expense. Stock-based compensation expense increased $214,000, reflecting additional stock option grants to employees and members of the Board of Directors as part of the Company’s overall compensation program.
Personnel-related costs increased $228,000, primarily due to higher bonus expense reflecting the Company’s progress towards the achievement of 2026 performance objectives.
Professional fees decreased by $81,000, driven by $156,000 of lower legal expenses following the settlement of a legal matter earlier in 2026. This decrease was partially offset by $68,000 in strategic consulting fees incurred in 2025 and $25,000 in higher Board compensation resulting from an increase in the number of Board members and changes in director compensation rates, responsibilities, and committee assignments.
Interest Income, Net
For the third quarter of 2026, interest income, net was $35,000, consisting of $40,000 in interest income and $5,000 in interest expense. This compares to interest income, net of $49,000 in the third quarter of 2025, consisting of $55,000 in interest income and $6,000 in interest expense. The decrease in interest income in 2026 reflects a lower average balance of cash, cash equivalents and investments compared to the same period in 2025.
22

Table of Contents
Comparison of the Nine Months Ended September 30, 2026 and 2025
The following table summarizes our results of operations for the periods presented (dollars in thousands):
Nine Months Ended September 30,Change
20262025AmountPercent
Revenues, net$2,360 $1,800 $560 31 %
Cost of sales659 645 14 2 
Gross profit1,701 1,155 546 47 
Operating expenses:
Research and development1,217 1,245 (28)(2)
Sales and marketing2,218 1,277 941 74 
General and administrative4,238 3,257 981 30 
Total operating expenses7,673 5,779 1,894 33 
Loss from operations(5,972)(4,624)(1,348)29 
Interest income, net121 45 76 169 
Net loss$(5,851)$(4,579)$(1,272)28 
Revenues
Revenues for the periods presented consisted of the following (dollars in thousands):
Nine Months Ended September 30,Change
20262025AmountPercent
By product line:
Evolve$2,058 87 %$1,489 83 %$569 38 %
ContraPest302 13 311 17 (9)(3)
$2,360 100 %$1,800 100 %$560 31 
By sales channel:
E-commerce$1,467 62 %$482 27 %$985 204 
B2B893 38 1,318 73 (425)(32)
$2,360 100 %$1,800 100 %$560 31 
Sales, net of sales discounts and promotions, were $2.4 million for the nine months ended September 30, 2026, compared to $1.8 million for the same period of 2025. The $560,000 increase was driven by higher sales volume of Evolve, supported by continued growth in our e-commerce sales channel. Evolve represented approximately 87% of revenues for the nine months ended September 30, 2026, compared to 83% in the same period of 2025, reflecting the continued shift in our product mix toward Evolve. The increase in Evolve sales was partially offset by lower ContraPest sales, which primarily occur through our B2B sales channel, resulting in an overall shift in our revenue mix toward e-commerce during the period. With the sales and marketing organizations now established and continuing to evolve, we expect B2B sales to increase. B2B sales were also impacted by the transition of Amazon management in-house in February of 2026, which shifted sales from the B2B channel to the e-commerce channel.
Cost of Sales
Cost of sales consists of costs related to products sold, including scrap and any reserves for obsolescence, as well as shipping costs when charged to the customer. Cost of sales was $659,000, or 27.9% of net sales, for the nine months ended September 30, 2026, compared to $645,000, or 35.8%, for the same period of 2025.
23

Table of Contents
Gross Profit
Gross profit for the nine months ended September 30, 2026 was $1.7 million, representing a margin of 72.1%, compared to $1.2 million, or 64.2% margin, for the same period of 2025. The improvement reflects the same factors affecting the quarterly comparison and demonstrates continued progress in the execution of our commercialization strategy.
Research and Development Expenses
Research and development expenses consisted of the following (in thousands):
Nine Months Ended September 30,Change
20262025AmountPercent
Personnel related (including stock-based compensation)$706 $675 $31 5 %
Facility related302 308 (6)(2)
Depreciation91 85 6 7 
Supplies, maintenance and other118 177 (59)(33)
Total$1,217 $1,245 $(28)(2)
Research and development expenses were $1.2 million for the nine months ended September 30, 2026, compared to $1.2 million for the same period of 2025, representing a decrease of $28,000. The decrease was primarily attributable to lower supplies and maintenance expenses and partially offset by higher personnel-related costs, reflecting increased bonus expense associated with the progress towards the achievement of 2026 performance objectives. Facility-related expenses were comparable between periods, as higher costs incurred in 2026 were offset by incremental expenses incurred in 2025 related to the transition between manufacturing facilities.
Sales and Marketing Expenses
Sales and marketing expenses consisted of the following (in thousands):
Nine Months Ended September 30,Change
20262025AmountPercent
Personnel related (including stock-based compensation)$685 $532 $153 29 %
Professional fees520 210 310 148 
Marketing and advertising388 203 185 91 
Retailer and third party fees and commissions358 74 284 384 
Other267 258 9 3 
Total$2,218 $1,277 $941 74 
Sales and marketing expenses were $2.2 million for the nine months ended September 30, 2026, compared to $1.3 million for the same period of 2025, representing an increase of $941,000. The increase in personnel related expense increased due to an increase in sales headcount and increased commissions and incentives. The increase in retailer and third party fees and commissions is due to bringing the Company’s Amazon business in-house. The increases in marketing and advertising and professional fees reflect the increased investment in brand and product awareness, and are expected to moderate as the Company reduces its reliance on consultants who supported personnel transitions within the sales and marketing organizations and completes its strategic initiatives.
Personnel-related costs increased $153,000, primarily due to turnover within the sales organization early in 2026, which resulted in $196,000 of severance costs that are not expected to recur. During 2026, both the sales and marketing organizations underwent significant changes. By the third quarter of 2026, these organizations had become established, while continuing to evolve to drive the Company’s commercial growth strategy.
24

Table of Contents
Professional fees increased by $310,000, with higher consulting to support the sales and marketing organizations during personnel transitions and to advance strategic sales and marketing initiatives, including product packaging redesign, marketing strategy development, and the transition to direct sales on Amazon. As the personnel transitions within the sales and marketing organizations and these strategic initiatives have largely been completed, we expect consulting costs to moderate in the coming quarters.
Marketing and advertising increased $185,000, primarily reflecting the hiring and stabilization of the marketing team, which has established the personnel infrastructure needed to support the Company’s commercialization strategy, as well as increased spending on advertising initiatives to support the continued ramp-up of Amazon sales activity and drive growth through our e-commerce sales channel.
Retailer and third party fees and commissions increased $284,000, primarily due to bringing third-party marketplace management, including Amazon, in-house, as discussed above, as well as continued growth in our e-commerce sales channel.
General and Administrative Expenses
General and administrative expenses consisted of the following (in thousands):
Nine Months Ended September 30,Change
20262025AmountPercent
Personnel related$1,661 $1,072 $589 55 %
Professional fees1,607 1,309 298 23 
Stock-based compensation453 213 240 113 
Insurance158 146 12 8 
Other359 517 (158)(31)
Total$4,238 $3,257 $981 30 
General and administrative expenses were $4.2 million for the nine months ended September 30, 2026, compared to $3.3 million for the same period of 2025, representing an increase of $981,000. The overall increase reflects non-recurring costs associated with leadership transition and succession, as well as legal expenses related to a specific matter. These costs total approximately $788,000 and are not expected to recur.
Personnel-related costs increased $589,000, primarily due to leadership transition and succession activities which included $169,000 in 2026 related to the addition of an Interim Chief Operating Officer in November 2025 and $276,000 of severance costs in 2026, neither of which is expected to recur. In addition, the increase reflects higher bonus expense resulting from the Company’s progress towards the achievement of 2026 performance objectives.
Professional fees increased by $298,000. Board cash compensation increased by $140,000, primarily due to an increase in the number of Board members ($26,000), changes in director responsibilities and committee assignments ($26,000), compensation paid to a Board member who previously received such compensation in stock options ($40,000), and an increase to base fees following a compensation review ($48,000).
Legal fees increased by $298,000, primarily reflecting costs associated with the leadership transition, employee-related matters, and changes in legal counsel, including differences in the nature and volume of legal services provided and hourly billing rates. In addition, compensation of $86,000 was incurred in connection with the appointment of an Interim Executive Chair during the early part of 2026, and executive search expenses increased by $60,000 in connection with the leadership succession. These increases were partially offset by a $139,000 decrease in legal expenses following the settlement of a legal matter earlier in 2026 and $68,000 in strategic consulting fees incurred in 2025.
Stock-based compensation was higher related to stock option grants to employees and members of the Board of Directors as part of the Company’s overall compensation program.
Other general and administrative expenses decreased, primarily reflecting $111,000 in lower franchise fees and other operating costs as a result of ongoing cost-containment efforts.
25

Table of Contents
Interest Income, Net
For the nine months ended September 30, 2026, interest income, net was $121,000, consisting of $135,000 in interest income and $14,000 in interest expense. This compares to interest income, net of $45,000, consisting of $62,000 in interest income and $17,000 in interest expense, for the same period of 2025. The increase in interest income in 2026 reflects a higher average balance of cash, cash equivalents and investments compared to the same period in 2025.
Liquidity and Capital Resources
Liquidity
Since our inception, we have incurred operating losses related to our research and development activities and commercialization efforts, with a net loss of $5.9 million for the nine months ended September 30, 2026, and we expect these losses to continue for the near future. Although sales of our products have increased in each of the last three years—20% in 2025, 56% in 2024, and 17% in 2023—we are not yet able to fund operations by product sales alone. We have primarily funded our operations through the sale of equity securities, including common stock and warrants to purchase common stock.
Through September 30, 2026, we received net proceeds of $117.2 million primarily from the sales of our equity securities, including warrant exercises, an aggregate of $10.1 million in product sales and an aggregate of $1.7 million from licensing fees. As of September 30, 2026, cash and cash equivalents were $4.0 million, compared to cash and cash equivalents and short-term investments of $8.6 million as of December 31, 2025.
Based on our current operating plan, we believe that our cash and cash equivalents as of November 12, 2026, together with anticipated revenue and current operating expense levels, will be sufficient to fund our operations for approximately nine months. This estimate assumes no material changes in working capital requirements. Increased revenues, reduced operating expenses, or additional financing, if obtained, would further extend our cash runway.
Our projected cash runway does not assume the receipt of additional capital from equity issuances, debt financings, strategic partnerships, or other external sources. While we have evaluated and continue to evaluate our operating expenses and have focused our resources on the successful commercialization of fertility control products in the United States, additional financing will be needed in order to fund our operating losses before achieving our revenue and margin targets and becoming profitable and generating positive cash flows. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If revenue growth does not occur at anticipated levels, or if expenses exceed current expectations, we may be required to seek additional financing sooner than currently anticipated.
We continue to evaluate various financing alternatives, including equity offerings under our existing ATM Facility, strategic partnerships, and other capital-raising transactions. There can be no assurance that additional capital will be available on acceptable terms, if at all. If equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate our commercialization and development efforts, sell certain assets, or discontinue operations, or we may be required to take other measures that could impair our ability to be successful and operate as a going concern. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest could be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and may be secured by all or a portion of our assets. If we fail to obtain additional capital as and when required, such failure could have a material adverse effect on our business, results of operations and financial condition.
Additional Funding Requirements
Our expenses may continue to increase in connection with our ongoing activities, particularly as we focus on marketing and sales of fertility control products. In addition, we will continue to incur costs associated with operating as a public company.
26

Table of Contents
In particular, we expect to incur increased expenses as we:
•work to maximize market acceptance for, and generate sales of, our products, including by conducting field demonstrations for potential lead customers;
•explore strategic partnerships to enable us to penetrate additional target markets and geographical locations;
•manage the infrastructure for sales, marketing and distribution of fertility control products and any other product candidates for which we may receive regulatory approval;
•seek additional regulatory approvals for fertility control products, including to more fully expand the market and use for fertility control products and, if we believe there is commercial viability, for our other product candidates;
•further develop our manufacturing processes to contain costs while being able to scale to meet future demand of fertility control products and any other product candidates for which we receive regulatory approval;
•continue product development of fertility control products and advance our research and development activities and, as our operating budget permits, advance the research and development programs for other product candidates;
•maintain and protect our intellectual property portfolio; and
•add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company.
We will need additional financing to fund these continuing and additional expenses.
Capital Resources
The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):
Nine Months Ended September 30,
20262025
Cash and cash equivalents, beginning of period$7,575 $1,307 
Net cash provided by (used in):
Operating activities(4,960)(4,086)
Investing activities982 (3,089)
Financing activities354 13,146 
Increase (decrease) in cash and cash equivalents(3,624)5,971 
Cash and cash equivalents, end of period$3,951 $7,278 
Cash Flows from Operating Activities—Cash flows from operating activities are generally determined by the amount and timing of cash received from customers and payments made to vendors, as well as the nature and amount of non-cash items, including depreciation and amortization and stock-based compensation included in operating results during a given period.
During the nine months ended September 30, 2026, operating activities used $5.0 million of cash, resulting from our net loss of $5.9 million, partially offset by net non-cash charges of $591,000, consisting primarily of stock-based compensation, depreciation and amortization, and operating lease expenses, and a $300,000 net increase in cash resulting from changes in operating assets and liabilities. Our net loss was driven by costs related to our selling, marketing, general and administrative activities resulting from our continued efforts to commercialize our products, combined with research and development costs related to our continued efforts on formulations of new products and improvements to existing products. The net increase in cash from changes in operating assets and liabilities primarily resulted from an increase in accounts payable and accrued expenses of $406,000 and a decrease in inventory of $28,000. This increase was partially offset by a $101,000 increase in prepaid expenses and a $46,000 increase in accounts receivable.
27

Table of Contents
During the nine months ended September 30, 2025, operating activities used $4.1 million of cash. This consisted of a net loss of $4.6 million, partially offset by $418,000 of non-cash charges, consisting primarily of stock-based compensation, depreciation and amortization, and operating lease expenses, and a $75,000 net increase in cash resulting from changes in operating assets and liabilities. The net loss was primarily attributable to selling, marketing, general and administrative expenses associated with our efforts to commercialize our products, as well as research and development expenses. The net increase in cash from changes in operating assets and liabilities primarily resulted from an increase in accounts payable and accrued expenses of $77,000 and decreases in prepaid expenses of $64,000, inventory of $27,000, and other assets related to the return of facility deposits of $22,000. This increase was partially offset by a $125,000 increase in accounts receivable.
Cash Flows from Investing Activities—Cash flows from investing activities consist of transactions involving held-to-maturity investments and purchases of property and equipment. For the nine months ended September 30, 2026, investing activities provided $1.0 million of cash, consisting of $1.0 million from the maturity of a held-to-maturity investment, partially offset by $18,000 of purchases of property and equipment. For the nine months ended September 30, 2025, investing activities used $3.1 million of cash, consisting of $3.0 million of purchases of held-to-maturity investments and $125,000 of purchases of property and equipment.
Cash Flows from Financing Activities—Financing activities provide cash for both day-to-day operations and capital requirements as needed. For the nine months ended September 30, 2026, net cash provided by financing activities consisted of $400,000 of net proceeds received from the issuance of common stock under our ATM Facility, partially offset by $46,000 of repayments on notes payable. For the nine months ended September 30, 2025, net cash provided by financing activities consisted of $10.5 million of net proceeds received from the exercise of warrants and $2.7 million of net proceeds from the issuance of common stock under our ATM Facility, partially offset by $42,000 of repayments on notes payable.
Critical Accounting Policies and Estimates
There have been no material changes to our critical accounting policies and estimates as previously disclosed in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We periodically conduct evaluations (pursuant to Rule 13a-15(b) under the Exchange Act), under the supervision and with the participation of management, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q.
These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that this information is accumulated and communicated to management, including the principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of the end of the period covered by this report.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
28

Table of Contents
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may be a party to certain legal proceedings, incidental to the normal course of business.
Item 1A. Risk Factors
Except as set forth below, there have been no material changes to our risk factors set forth in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026. The risk factors set forth below supplement, and should be read together with, the risk factors described in our Annual Report on Form 10-K.
Ownership of our common stock is concentrated among a small number of stockholders, who are able to exert significant influence over matters requiring stockholder approval and may seek to influence our business strategies and operations, which could divert management resources and adversely affect our business.
As of October 30, 2026, two of our stockholders beneficially owned an aggregate of approximately 45% of our outstanding common stock. As a result, these stockholders are able to exert significant influence over matters requiring stockholder approval, including the election of directors, amendments to our organizational documents and the approval of significant corporate transactions, such as a merger or a sale of all or substantially all of our assets. This concentration of ownership may also delay, prevent or discourage unsolicited acquisition proposals or other offers for our common stock that you may believe are in your best interest as a stockholder. The interests of these stockholders may not always coincide with the interests of our other stockholders.
Further, sales of a substantial number of shares of our common stock by either of these stockholders, or the perception that such sales could occur, could cause the market price of our common stock to decline. Any of these circumstances could adversely affect our business, financial condition, results of operations and the market price of our common stock.
We may not be able to comply with all applicable listing requirements or standards of The Nasdaq, and Nasdaq could delist our common stock.
Our common stock is listed on Nasdaq. In order to maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards. Previously, on September 26, 2018, March 20, 2019, February 20, 2020, March 2, 2022, August 25, 2023 and, most recently, on October 20, 2026, we received a letter from the listing qualifications staff of Nasdaq (the “Staff”) providing notification that the bid price for our common stock had closed below $1.00 per share for the previous 30 consecutive business days and our common stock no longer met the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). In each case, in accordance with Nasdaq Listing Rule 5810(c)(3) (A), we had an initial period of 180 calendar days to regain compliance.
In the event that we are unable to become compliant with any of the minimum financial and other continued listing requirements of the Nasdaq and re-establish compliance within the require timeframe, our common stock could be delisted from the Nasdaq, which could have a material adverse effect on our financial condition and which would cause the value of our common stock to decline. If our common stock is not eligible for listing or quotation on another market or exchange, trading of our common stock could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it would become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely be a reduction in our coverage by security analysts and the news media, which could cause the price of our common stock to decline further. In addition, it may be difficult for us to raise additional capital if we are not listed on a national securities exchange.
Item 5. Other Information
During the quarter ended September 30, 2026, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).
29

Table of Contents
Item 6. Exhibits
Exhibit
Number
Description
10.1*
10.2*
31.1
31.2
32.1
32.2
101.INSInline XBRL Instance Document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
* Incorporated by reference.
30

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
SENESTECH, INC.
Date: November 13, 2026
By:
/s/ Michael Edell
Michael Edell
President and Chief Executive Officer
(Principal Executive Officer)
Date: November 13, 2026
By:/s/ Thomas C. Chesterman
Thomas C. Chesterman
Executive Vice President, Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer)
31